Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Maede Khalifeloo, Soofia Naghdi, Noureddin Nakhostin Ansari, Jan Dommerholt & Mohammad Ali Sahraian. (2022) Dry needling for the treatment of muscle spasticity in a patient with multiple sclerosis: a case report. Physiotherapy Theory and Practice 38:13, pages 3248-3254.
Read now
Read now
Gavin Williams, Barby J. Singer, Stephen Ashford, Brian Hoare, Tandy Hastings-Ison, Klemens Fheodoroff, Steffen Berwick, Edwina Sutherland & Bridget Hill. (2022) A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children. Disability and Rehabilitation 44:4, pages 509-519.
Read now
Read now
Chueh Lin Hsu, Piotr Iwanowski, Chueh Hsuan Hsu & Wojciech Kozubski. (2021) Genetic diseases mimicking multiple sclerosis. Postgraduate Medicine 133:7, pages 728-749.
Read now
Read now
Rafael Arroyo González. (2018) A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis. Expert Review of Neurotherapeutics 18:10, pages 785-791.
Read now
Read now
Oscar Fernández, Miguel Angel Calleja-Hernández, José Meca-Lallana, Celia Oreja-Guevara, Ana Polanco & Ferran Pérez-Alcántara. (2017) Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Review of Pharmacoeconomics & Outcomes Research 17:4, pages 321-333.
Read now
Read now
Sven G Meuth, Carlos Vila & Kerry L Dechant. (2015) Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Review of Neurotherapeutics 15:8, pages 909-918.
Read now
Read now
Jürgen Koehler, Wolfgang Feneberg, Martin Meier & Walter Pöllmann. (2014) Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. International Journal of Neuroscience 124:9, pages 652-656.
Read now
Read now
Rafael Arroyo, Mariona Massana & Carlos Vila. (2013) Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. International Journal of Neuroscience 123:12, pages 850-858.
Read now
Read now
Carlo Pozzilli. (2013) Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Review of Neurotherapeutics 13:sup2, pages 49-54.
Read now
Read now
Ralf Gold. (2013) Multiple sclerosis spasticity epidemiology – key publications. Expert Review of Neurotherapeutics 13:sup2, pages 45-46.
Read now
Read now
Articles from other publishers (52)
Mashael A Ismail & Naglaa M Elsayed. (2023) Diffusion-Weighted Images and Contrast-Enhanced MRI in the Diagnosis of Different Stages of Multiple Sclerosis of the Central Nervous System. Cureus.
Crossref
Crossref
Montse Artola, Ana Hernando, Oscar Vidal, Núria Vidal, Ester Cuenca, Rosalía Horno, Miguel Ángel Robles, Clara Oriol, Silvia Peralta, M. A. José Solana, Matilde Rubio, Cristina Montero, Mercè Lleixà, Cinta Zabay, Montse Martin, Isabel Leon, Consuelo Molinos, Mandi Matamoros, Laura Mercadé, Olga Fornali, Laura Montero, Albert Saiz & Núria Solà‐Valls. (2022) The role of specialist nurses in detecting spasticity and related symptoms in multiple sclerosis. Journal of Clinical Nursing 32:13-14, pages 3496-3503.
Crossref
Crossref
Djamel Bensmail, Pierre Karam, Anne Forestier, Jean-Yves Loze & Jonathan Lévy. (2023) Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study. Toxins 15:4, pages 280.
Crossref
Crossref
Michael Guger, Robert Hatschenberger & Fritz Leutmezer. (2023) Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria. Brain and Behavior 13:4.
Crossref
Crossref
Mansour A Alghamdi, Khaled Abdulwahab Amer, Abdulrahman Ali S Aldosari, Razan Saeed Al-Maalwi, Sereen Dhafer Al-Muhsin, Arwa Abdulwahab Amer, Shahd Abdulhakeem Al Hamdan, Ahmed H. Sakah, Mohammed Abadi Alsaleem & Laith AL-Eitan. (2023) Assessment of Impact of Spasticity on Activities of Daily Living in Multiple Sclerosis Patients from Saudi Arabia: A Cross-sectional Study. The Open Public Health Journal 16:1.
Crossref
Crossref
İlknur Özkan, Cansu Polat Dunya & Serkan Demir. (2022) Life Experiences of Patients With Multiple Sclerosis About Their Spasticity: A Phenomenological Study. Clinical Nursing Research 32:1, pages 49-59.
Crossref
Crossref
Alireza Emadi, Sara Halakoo, Cyrus Taghizadeh Delkhoush & Fatemeh Ehsani. (2023) The Effects of Neuromodulators on Spasticity, Balance, and Gait in Patients with MS: A Systematic Review and Meta-Analysis Study. European Neurology 86:2, pages 144-154.
Crossref
Crossref
SD Newsome, B Thrower, B Hendin, S Danese, J Patterson & R Chinnapongse. (2022) Symptom Burden, Management and Treatment Goals of People with MS Spasticity: Results from SEEN-MSS, a Large-scale, Self-reported Survey. Multiple Sclerosis and Related Disorders, pages 104376.
Crossref
Crossref
Francesco Patti, Clara Grazia Chisari, Óscar Fernández, Jorge Sarroca, Elena Ferrer‐Picón, Francisco Hernández Vicente & Carlos Vila Silván. (2022) A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’. European Journal of Neurology 29:9, pages 2744-2753.
Crossref
Crossref
Andrew Chan & Carlos Vila Silván. (2022) Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap. Neurodegenerative Disease Management 12:3, pages 141-154.
Crossref
Crossref
Johanna Engelhard, Denise M. Oleske, Sarah Schmitting, Karen E. Wells, Saritha Talapala & Luigi M. Barbato. (2022) Multiple sclerosis by phenotype in Germany. Multiple Sclerosis and Related Disorders 57, pages 103326.
Crossref
Crossref
Marie D’hooghe, Barbara Willekens, Valerie Delvaux, Miguel D’haeseleer, Daniel Guillaume, Guy Laureys, Guy Nagels, Patrick Vanderdonckt, Vincent Van Pesch & Veronica Popescu. (2021) Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience. BMC Neurology 21:1.
Crossref
Crossref
Arianna Sartori, Alessandro Dinoto, Lara Stragapede, Giulia Mazzon, Maria Elisa Morelli, Fulvio Pasquin, Alessio Bratina, Antonio Bosco & Paolo Manganotti. (2021) Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience. Neurological Sciences 42:12, pages 5037-5043.
Crossref
Crossref
Oscar Fernandez, Lucienne Costa-Frossard, Maria Luisa Martínez-Ginés, Paloma Montero, Jose María Prieto-González & Lluís Ramió-Torrentà. (2021) Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology. Frontiers in Neurology 12.
Crossref
Crossref
Paolo De Blasiis, Maria Francesca Siani, Allegra Fullin, Mario Sansone, Mariarosa Anna Beatrice Melone, Simone Sampaolo, Elisabetta Signoriello & Giacomo Lus. (2021) Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.. Multiple Sclerosis and Related Disorders 51, pages 102805.
Crossref
Crossref
Clayton W. Swanson, Felix Proessl, Jaclyn A. Stephens, Augusto A. Miravalle & Brett W. Fling. (2021) Non-invasive brain stimulation to assess neurophysiologic underpinnings of lower limb motor impairment in multiple sclerosis. Journal of Neuroscience Methods 356, pages 109143.
Crossref
Crossref
Ursula S. Hofstoetter, Brigitta Freundl, Peter Lackner & Heinrich Binder. (2021) Transcutaneous Spinal Cord Stimulation Enhances Walking Performance and Reduces Spasticity in Individuals with Multiple Sclerosis. Brain Sciences 11:4, pages 472.
Crossref
Crossref
Friedemann Paul & Carlos Vila Silván. (2021) Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. Neurodegenerative Disease Management 11:2, pages 143-153.
Crossref
Crossref
Antonella Conte & Carlos Vila Silván. (2021) Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity. Neurodegenerative Diseases 21:3-4, pages 55-62.
Crossref
Crossref
Maria Fernanda Arboleda & Erin Prosk. 2021. Cannabinoids and Pain. Cannabinoids and Pain
153
165
.
Francesco Patti, Clara Grazia Chisari, Claudio Solaro, Maria Donata Benedetti, Eliana Berra, Assunta Bianco, Roberto Bruno Bossio, Fabio Buttari, Letizia Castelli, Paola Cavalla, Raffaella Cerqua, Gianfranco Costantino, Claudio Gasperini, Angelica Guareschi, Domenico Ippolito, Roberta Lanzillo, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Margherita Russo, Francesco Saccà, Giovanna Salamone, Elisabetta Signoriello, Gabriella Spinicci, Daniele Spitaleri, Eleonora Tavazzi, Maria Trotta, Mauro Zaffaroni & Mario Zappia. (2020) Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. Neurological Sciences 41:10, pages 2905-2913.
Crossref
Crossref
Yesung Cha & Arash Arami. (2020) Quantitative Modeling of Spasticity for Clinical Assessment, Treatment and Rehabilitation. Sensors 20:18, pages 5046.
Crossref
Crossref
Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto & Lluis Ramió. (2020) The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms. Frontiers in Neurology 11.
Crossref
Crossref
Niklas Frahm, Michael Hecker & Uwe Klaus Zettl. (2019) Polypharmacy in patients with multiple sclerosis: a gender-specific analysis. Biology of Sex Differences 10:1.
Crossref
Crossref
Gareth Pryce & David Baker. 2019. Emerging Drugs and Targets for Multiple Sclerosis. Emerging Drugs and Targets for Multiple Sclerosis
241
263
.
Francesco Patti. (2019) Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies. Neurodegenerative Disease Management 9:2s, pages 3-7.
Crossref
Crossref
J. Korzhova, I. Bakulin, D. Sinitsyn, A. Poydasheva, N. Suponeva, M. Zakharova & M. Piradov. (2019) High‐frequency repetitive transcranial magnetic stimulation and intermittent theta‐burst stimulation for spasticity management in secondary progressive multiple sclerosis. European Journal of Neurology 26:4, pages 680-e44.
Crossref
Crossref
Kathryn C. Fitzgerald, Amber Salter, Tuula Tyry, Robert J. Fox, Gary Cutter, Ellen M. Mowry & Ruth Ann Marrie. (2019) Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. Multiple Sclerosis and Related Disorders 29, pages 86-93.
Crossref
Crossref
Katja Akgün, Ute Essner, Cordula Seydel & Tjalf Ziemssen. (2019) Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. Journal of Central Nervous System Disease 11, pages 117957351983199.
Crossref
Crossref
Peter Flachenecker, Francesco Saccà & Carlos Vila. (2018) Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings. Case Reports in Neurology 10:2, pages 169-176.
Crossref
Crossref
Javier Mallada Frechín. (2018) Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study. Neurodegenerative Disease Management 8:3, pages 151-159.
Crossref
Crossref
Guillermo Izquierdo. (2017) Multiple sclerosis symptoms and spasticity management: new data. Neurodegenerative Disease Management 7:6s, pages 7-11.
Crossref
Crossref
Sabrina Giacoppo, Placido Bramanti & Emanuela Mazzon. (2017) Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation. Multiple Sclerosis and Related Disorders 17, pages 22-31.
Crossref
Crossref
O. M. R?nning & K. D. Tornes. (2017) Need for symptomatic management in advanced multiple sclerosis. Acta Neurologica Scandinavica 135:5, pages 529-532.
Crossref
Crossref
Melanie E. M. Kelly, Christian Lehmann & Juan Zhou. (2017) The Endocannabinoid System in Local and Systemic Inflammation. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 9:2, pages i-192.
Crossref
Crossref
P. Ertzgaard, M. Anhammer & A. Forsmark. (2017) Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap. Acta Neurologica Scandinavica 135:3, pages 366-372.
Crossref
Crossref
Dirk Dressler, Roongroj Bhidayasiri, Saeed Bohlega, Abderrahmane Chahidi, Tae Mo Chung, Markus Ebke, L. Jorge Jacinto, Ryuji Kaji, Serdar Koçer, Petr Kanovsky, Federico Micheli, Olga Orlova, Sebastian Paus, Zvezdan Pirtosek, Maja Relja, Raymond L. Rosales, José Alberto Sagástegui-Rodríguez, Paul W. Schoenle, Gholam Ali Shahidi, Sofia Timerbaeva, Uwe Walter & Fereshte Adib Saberi. (2016) Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. Journal of Neurology 264:1, pages 112-120.
Crossref
Crossref
María Asunción Fernández-Pablos, Lucienne Costa-Frossard, Carlos García-Hernández, Inmaculada García-Montes & Matilde Escutia-Roig. (2016) Manejo de los síntomas asociados a la espasticidad en pacientes con esclerosis múltiple. Enfermería Clínica 26:6, pages 367-373.
Crossref
Crossref
Uwe K. Zettl, Paulus Rommer, Petra Hipp & Robert Patejdl. (2015) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Therapeutic Advances in Neurological Disorders 9:1, pages 9-30.
Crossref
Crossref
Mar Tintoré. (2015) Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis. Neurodegenerative Disease Management 5:6s, pages 15-17.
Crossref
Crossref
G. Coghe, M. Pau, F. Corona, J. Frau, L. Lorefice, G. Fenu, G. Spinicci, E. Mamusa, L. Musu, S. Massole, R. Massa, M. G. Marrosu & E. Cocco. (2015) Walking improvements with nabiximols in patients with multiple sclerosis. Journal of Neurology 262:11, pages 2472-2477.
Crossref
Crossref
Tatjana Knezevic, Ljubica Konstantinovic, Sindi Rodic, Calogero Foti, Jelena Drulovic, Jelena Dackovic, Dejan Nikolic, Ivana Petronic & Dobrivoje S. Stokic. (2015) Validity and reliability of the Serbian version of Patient-Reported Impact of Spasticity Measure in multiple sclerosis. International Journal of Rehabilitation Research 38:3, pages 199-205.
Crossref
Crossref
Jose Eustasio Meca‐Lallana, Rocío Hernández‐Clares & Ester Carreón‐Guarnizo. (2015) Spasticity in multiple sclerosis and role of glatiramer acetate treatment. Brain and Behavior 5:9.
Crossref
Crossref
Maria Trojano & Carlos Vila. (2015) Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study. European Neurology 74:3-4, pages 178-185.
Crossref
Crossref
Patrick Vermersch. (2014) MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study. Neurodegenerative Disease Management 4:6, pages 407-415.
Crossref
Crossref
Rafael Arroyo, Carlos Vila & Kerry L Dechant. (2014)
Impact of Sativex
®
on quality of life and activities of daily living in patients with multiple sclerosis spasticity
. Journal of Comparative Effectiveness Research 3:4, pages 435-444.
Crossref
Crossref
L. Lorente Fernández, E. Monte Boquet, F. Pérez-Miralles, I. Gil Gómez, M. Escutia Roig, I. Boscá Blasco, J.L. Poveda Andrés & B. Casanova-Estruch. (2014) Clinical experiences with cannabinoids in spasticity management in multiple sclerosis. Neurología (English Edition) 29:5, pages 257-260.
Crossref
Crossref
L. Lorente Fernández, E. Monte Boquet, F. Pérez-Miralles, I. Gil Gómez, M. Escutia Roig, I. Boscá Blasco, J.L. Poveda Andrés & B. Casanova-Estruch. (2014) Experiencia clínica con los cannabinoides en la terapia de la espasticidad en la esclerosis múltiple. Neurología 29:5, pages 257-260.
Crossref
Crossref
P.J.H.L. Peeters, M.T. Bazelier, B.M.J. Uitdehaag, H.G.M. Leufkens, M.L. De Bruin & F. de Vries. (2014) The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink. Journal of Thrombosis and Haemostasis 12:4, pages 444-451.
Crossref
Crossref
Theodore R. KremerLinda R. Van DillenJoanne M. Wagner. (2014) Dynamometer-based measure of spasticity confirms limited association between plantarflexor spasticity and walking function in persons with multiple sclerosis. Journal of Rehabilitation Research and Development 51:6, pages 975-984.
Crossref
Crossref
Jürgen Koehler. (2014) Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience. European Neurology 71:Suppl. 1, pages 10-15.
Crossref
Crossref
Carlo Pozzilli. (2014) Overview of MS Spasticity. European Neurology 71:Suppl. 1, pages 1-3.
Crossref
Crossref